Siren L.L.C. Buys 250,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Siren L.L.C. lifted its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 23.2% during the first quarter, HoldingsChannel.com reports. The fund owned 1,328,698 shares of the company’s stock after purchasing an additional 250,000 shares during the period. Structure Therapeutics makes up approximately 1.8% of Siren L.L.C.’s investment portfolio, making the stock its 18th biggest holding. Siren L.L.C.’s holdings in Structure Therapeutics were worth $64,043,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Sterling Capital Management LLC bought a new position in shares of Structure Therapeutics during the first quarter worth $28,000. State of Wyoming acquired a new stake in Structure Therapeutics during the 2nd quarter worth $28,000. CWM LLC raised its stake in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 125 shares during the period. Assetmark Inc. lifted its holdings in Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after acquiring an additional 449 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Structure Therapeutics during the fourth quarter worth about $127,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 0.8%

GPCR stock opened at $50.80 on Friday. The stock has a 50-day moving average price of $45.21 and a two-hundred day moving average price of $55.90. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $15.80 and a 1 year high of $94.90. The stock has a market cap of $3.61 billion, a PE ratio of -58.39 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. On average, analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Canaccord Genuity Group began coverage on Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 price target for the company. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright lowered their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Wolfe Research initiated coverage on shares of Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.